Quanterix Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTRX research report →
Range $3 – $3
Price Chart
About the company
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection.
- CEO
- Everett V. Cunningham
- IPO
- 2017
- Employees
- 450
- HQ
- Billerica, MA, US
Get TickerSpark's AI analysis on QTRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $93.06M
- P/E
- -0.83
- PEG
- 0.18
- P/S
- 0.63
- P/B
- 0.42
- EV/EBITDA
- -0.98
- Div Yield
- 0.00%
- Gross Margin
- 41.65%
- Op Margin
- -79.19%
- Net Margin
- -75.05%
- ROE
- -42.99%
- ROIC
- -45.70%
Latest fiscal year · YoY change
- Revenue
- $138.65M+2.4%
- Gross Profit
- $64.72M-20.2%
- Op Income
- $-109,815,000
- Net Income
- $-107,150,000-178.1%
- EPS
- $-2.51-151.0%
- OCF Growth
- -119.6%
- FCF Growth
- -107.2%
- 52W High
- $8.77
- 52W Low
- $1.76
- 50D MA
- $3.02
- 200D MA
- $3.57
- Beta
- 1.04
- RSI (14)
- 30
- Avg Volume
- 721.60K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Quanterix said Q3 marked an early turnaround, with revenue beating expectations, consumables improving across the business, and diagnostics momentum building around LucentAD Complete and new partnerships.· November 9, 2026
- Q3 revenue was $35 million, up 6.3% sequentially but down 13.1% year over year; pro forma year-over-year decline was 8.6%.
- Non-GAAP gross margin improved to 47.4%, up 150 basis points year over year, helped by Akoya synergies and cost optimization.
- Spatial consumables were a standout, reaching the second-highest level ever in Q3 and driving the strongest consumables growth.
- Diagnostics traction improved as LucentAD Complete test volume more than doubled sequentially and Florida Medicaid coverage was finalized at $484 per test.
- Management narrowed full-year 2026 revenue guidance to $142 million-$146 million and expects the commercial reset to matter more in 2027.
Quanterix reported Q3 2026 total revenue of $35 million, up 6.3% sequentially from Q2 and down 13.1% from Q3 2025 reported revenue of $40.2 million. On a pro forma basis, excluding $2.4 million from a terminated diagnostic development program and including Akoya pre-acquisition revenue of $0.6 million, the year-over-year decline was 8.6%. GAAP gross profit was $13.5 million with gross margin of 38.6%; non-GAAP gross profit was $16.6 million and non-GAAP gross margin was 47.4%, up 150 basis points year over year. Net loss was $21.6 million, adjusted EBITDA loss was $12.2 million, and cash usage was $16.2 million; cash ended at approximately $80.7 million. For full-year 2026, management narrowed revenue guidance to approximately $142 million to $146 million, kept non-GAAP gross margin guidance at 48% to 50%, and expects to end 2026 with about $70 million in cash and no debt.
Everett Cunningham framed Q3 as the first proof point in restoring growth, saying the company exceeded top-line expectations and saw improvement across the business despite market softness. He emphasized a refreshed commercial structure, stronger leadership, new product launches, and expanding diagnostics partnerships as key catalysts for 2026 and 2027. His tone was constructive and optimistic, but he repeatedly noted it is still early and that the full impact of the changes will take time.
Jason Faessler focused on the numbers behind the turnaround: $35 million in revenue, 47.4% non-GAAP gross margin, $35.4 million in non-GAAP operating expenses, $21.6 million net loss, and $12.2 million adjusted EBITDA loss. He said gross margin improved mainly from Akoya synergies and cost optimization, while operating expenses were managed with discipline even as the company invested in revenue-facing areas like diagnostics. He also highlighted cash preservation, noting $16.2 million of cash usage in the quarter, $80.7 million of ending cash, and an expected year-end cash balance of about $70 million with no debt.
Analysts asked whether SIMOA consumables were softer than expected; management said the issue was partly mix-related and partly timing, but pointed to product-focused commercial changes, new assay launches, and stronger CRO interest as supports for future growth. Questions also focused on diagnostics, where management said LucentAD Complete volume more than doubled sequentially, revenue remains relatively immaterial, and more disclosure will come later as the business scales. On FDA timing, Everett said discussions remain productive and the company is still optimistic about clearance, while on Florida Medicaid he corrected the reimbursement rate to $484 per test and said other states may follow.
The positive case from this call is that Quanterix appears to be stabilizing revenue after a long decline, with Q3 growth beating expectations and multiple operating indicators improving at once. Management pointed to better commercial execution, strong spatial consumables, rising Accelerator bookings, and real diagnostics progress through new lab partners and reimbursement coverage. The company also has new product launches and menu expansion that could support both research and diagnostics growth into 2027.
The main risks are that growth is still early and uneven, with revenue still down year over year and management saying the Q4 and 2027 benefits from the commercial reset are not yet fully visible. Diagnostics revenue is still described as relatively immaterial, FDA timing is uncertain, and broader market softness persists, especially in some end markets and regions. Cash usage remains significant, and management is still balancing investment for growth against preservation of cash.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.4%
- Shares Outstanding
- 47.48M
- Float Shares
- 38.17M
of shares held by institutions
136 13F filers
Buy/sell ratio 0.62. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.76M | ▲ 126.30K |
| Blue Water Life Science Advisors, LP | 3.47M | 0 |
| Vanguard Group Inc | 2.68M | ▲ 30.32K |
| First Eagle Investment Management, LLC | 2.19M | ▼ 560.66K |
| Portolan Capital Management, LLC | 1.84M | ▼ 59.11K |
| Vanguard Capital Management LLC | 1.80M | 0 |
| Lionhunter Capital Management, LLC | 1.72M | ▲ 222.39K |
| Marshall Wace, Llp | 1.19M | ▲ 221.09K |
| Geode Capital Management, LLC | 1.13M | ▲ 1.72K |
| State Street Corp | 900.54K | ▼ 31.77K |
| Prosight Management, LP | 825.00K | ▲ 825.00K |
| Aqr Capital Management LLC | 786.11K | ▼ 556.90K |
Held by 120 ETFs
Biggest fund positions in QTRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Miller Michael Francis | other | 834 |
| Nov 15, 26 | Miller Michael Francis | other | 249 |
| Nov 15, 26 | Miller Michael Francis | other | 372 |
| Nov 15, 26 | Miller Michael Francis | other | 111 |
| Nov 15, 26 | Miller Michael Francis | other | 135 |
| Nov 15, 26 | Miller Michael Francis | other | 41 |
| Nov 15, 26 | Miller Michael Francis | other | 136 |
| Nov 15, 26 | Miller Michael Francis | other | 41 |
| Nov 15, 26 | Miller Michael Francis | other | 81 |
| Nov 15, 26 | Miller Michael Francis | other | 25 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QTRX coverage
Recent articles, reports, and earnings notes.
No research on QTRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QTRX report →Quanterix Announces Leadership Transition Plan
businesswire.com · Nov 18
Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory
businesswire.com · Nov 16
ALZAI Health Corp. Enters into MOU with Quanterix Corporation to Advance Early Alzheimer's Disease Identification
newsfilecorp.com · Nov 13
Quanterix Corporation (QTRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Quanterix (QTRX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Quanterix Releases Financial Results for the Third Quarter of 2026
businesswire.com · Nov 9
Head-To-Head Comparison: Quantum-Si (NASDAQ:QSI) vs. Quanterix (NASDAQ:QTRX)
defenseworld.net · Nov 3
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
businesswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.